ALSO NOTED: Researchers assessing avian flu vaccine; Nastech pulls IPO; Isis extends drug collaboration; and much more...

> Health officials are scrambling to assess how they should respond to the news that an experimental vaccine for avian flu appears to work. Story

> Responding to chilly market conditions, Nastech Pharmaceutical of Bothell, Washington, has pulled its IPO. Release

> Isis Pharmaceuticals of Carlsbad, California, has extended its drug discovery collaboration with Eli Lilly. Release

> The FDA has approved a new five-day, 750 mg once-daily regimen for Levaquin tablets to treat acute bacterial sinusitis. Release

> Novelos Therapeutics of Newton, Massachusetts, is touting data from an early stage trial clinical study of non-small cell lung cancer. Release

And Finally... Americans' sensitivity to allergens has doubled in the last 30 years, with 54 percent responding to at least one of 10 allergens. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.